Difference between revisions of "Crizotinib (Xalkori)"
m (Text replacement - "[[Media:" to "[[File:") |
|||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Tyrosine kinase inhibitor; inhibits anaplastic lymphoma kinase (ALK), c-MET and subsequent expression of Hepatocyte Growth Factor Receptor (HGFR), and Recepteur d’Origine Nantais (RON). Inhibits activity of fusion proteins involving ALK, such as EML4-ALK and NPM-ALK.<ref name="insert">[http://labeling.pfizer.com/showlabeling.aspx?id=676 Crizotinib (Xalkori) package insert]</ref><ref>[[ | + | Class/mechanism: Tyrosine kinase inhibitor; inhibits anaplastic lymphoma kinase (ALK), c-MET and subsequent expression of Hepatocyte Growth Factor Receptor (HGFR), and Recepteur d’Origine Nantais (RON). Inhibits activity of fusion proteins involving ALK, such as EML4-ALK and NPM-ALK.<ref name="insert">[http://labeling.pfizer.com/showlabeling.aspx?id=676 Crizotinib (Xalkori) package insert]</ref><ref>[[File:Crizotinib.pdf | Crizotinib (Xalkori) package insert (locally hosted backup)]]</ref> |
<br>Route: PO | <br>Route: PO | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
Revision as of 23:13, 19 September 2021
General information
Class/mechanism: Tyrosine kinase inhibitor; inhibits anaplastic lymphoma kinase (ALK), c-MET and subsequent expression of Hepatocyte Growth Factor Receptor (HGFR), and Recepteur d’Origine Nantais (RON). Inhibits activity of fusion proteins involving ALK, such as EML4-ALK and NPM-ALK.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Crizotinib (Xalkori) package insert pages 15-18[1]
- Crizotinib (Xalkori) patient drug information (Chemocare)[3]
- Crizotinib (Xalkori) patient drug information (UpToDate)[4]
History of changes in FDA indication
Anaplastic large cell lymphoma
- 1/14/2021: Approved for pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. (New disease entity; based on ADVL0912)
Non-small cell lung cancer
- 8/26/2011: Initial accelerated approval for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive. (Based on PROFILE 1001)
- 11/20/2013: Approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive. (Indication removed from locally advanced setting; based on PROFILE 1007 and PROFILE 1014)
- 3/11/2016: Approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive. (New mutation-specific indication; based on PROFILE 1001)
Also known as
- Code names: PF02341066, PF-02341066
- Brand name: Xalkori